GO:0034450 ubiquitin-ubiquitin ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034450 (ubiquitin-ubiquitin ligase activity, synonym E4) catalyzes the isoenergetic transfer of ubiquitin from one ubiquitin-loaded thioester to an existing ubiquitin chain, extending the chain without ATP hydrolysis.
• E4 activity is mechanistically distinct from E1, E2, and E3 enzymes because it uses a preformed ubiquitin thioester as the donor and a ubiquitin chain as the acceptor.
• E4 enzymes such as LUBAC and CHFR build specific ubiquitin linkages (linear/M1 and K48-linked) that control NF-kB signaling, mitotic checkpoints, and protein quality control.
• Dysregulated ubiquitin-ubiquitin ligation is linked to cancer, neurodegeneration, and developmental disorders, making E4 enzymes attractive drug targets.
• Parkin and other RING-between-RING ligases use E4-like chemistry, and catalytic-domain mutations cause early-onset Parkinsonism.
• CRISPR knockout, point-mutation knock-in, and overexpression models are essential to dissect E4 enzyme function in cells and animals.
Description
Ubiquitin-ubiquitin ligase activity (GO:0034450), also known as E4 activity, is a molecular function that extends ubiquitin chains by transferring ubiquitin from a thioester-linked donor to an existing ubiquitin chain. This activity is distinguished from the canonical E1-E2-E3 cascade because it does not require ATP hydrolysis for the final transfer step; instead, it uses the energy stored in the thioester bond of a ubiquitin-conjugating enzyme or ubiquitin-loaded carrier. E4 enzymes are critical for building specific polyubiquitin linkages that determine substrate fate, including proteasomal degradation, signaling, and DNA repair. Researchers study GO:0034450 because it sits at the intersection of ubiquitin chain architecture and cellular decision-making. For example, the linear ubiquitin chain assembly complex (LUBAC) uses E4-like activity to generate M1-linked chains that activate NF-kB, and its dysregulation is implicated in immune disorders and cancer. Similarly, the checkpoint protein CHFR uses its RING-finger domain to assemble K48-linked chains that delay mitosis under stress. Understanding E4 mechanisms therefore informs drug discovery, biomarker development, and functional genomics. This article synthesizes authoritative QuickGO annotation and peer-reviewed literature to explain the definition, mechanism, key genes, disease relevance, and experimental models for GO:0034450. It is intended for molecular biologists, CRISPR engineers, and translational researchers who need a concise, citation-backed reference for ubiquitin-ubiquitin ligase activity.
ubiquitin-ubiquitin ligase activity At A Glance
| GO ID | GO:0034450 |
|---|---|
| GO term | ubiquitin-ubiquitin ligase activity |
| Ontology | molecular_function |
| Synonym | E4 |
| Major function | Elongation of ubiquitin chains by transfer of ubiquitin from a thioester-linked donor to an existing ubiquitin chain |
| Reaction | X-ubiquitin + Y-ubiquitin = Y-ubiquitin-ubiquitin + X |
| Linkage chemistry | Thioester bonds between the C-terminal glycine of ubiquitin and a cysteine sulfhydryl group |
| Energy requirement | Isoenergetic transfer; no additional ATP hydrolysis for the transfer step |
| Representative enzymes | LUBAC (linear ubiquitin chain assembly complex), CHFR, parkin |
What Is GO:0034450?
GO:0034450 describes the isoenergetic transfer of ubiquitin from one protein to an existing ubiquitin chain via the reaction X-ubiquitin + Y-ubiquitin = Y-ubiquitin-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue. In simpler terms, it is the enzymatic step that adds a ubiquitin molecule onto a growing ubiquitin chain using a pre-activated ubiquitin donor, without consuming ATP for the transfer itself.
Why Is ubiquitin-ubiquitin ligase activity Important in Cell Biology?
Ubiquitin-ubiquitin ligase activity is important because it determines the length and linkage type of polyubiquitin chains, which in turn dictate whether a substrate is degraded by the proteasome, redirected to lysosomes, or used as a signaling scaffold. E4 enzymes such as LUBAC and CHFR control fundamental processes including NF-kB activation, mitotic checkpoint signaling, and protein quality control, and their dysfunction is linked to cancer, immune disorders, and neurodegeneration. Because E4 activity is chemically distinct from E1/E2/E3 steps, it offers a selective target for therapeutic intervention and a unique node for CRISPR-based functional studies.
• E4 enzymes build specific ubiquitin linkages that determine substrate fate, including proteasomal degradation and signaling.
• LUBAC-mediated linear ubiquitination is essential for NF-kB activation and tissue homeostasis.
• CHFR uses E4-like activity to regulate the mitotic stress checkpoint and is frequently silenced in cancers.
• Parkin catalytic-domain mutations that impair E4-like chemistry cause early-onset Parkinsonism.
• Dysregulated ubiquitination is a hallmark of human disorders of proteasomal degradation.
• E4 activity is a potential drug target because it is mechanistically separable from E1/E2/E3 enzymes.
• Plant U-box E3 ligases with E4-like activity contribute to pathogen resistance, showing cross-kingdom relevance.
• FBXO2 and other substrate adaptors connect E4 activity to malignant tumor biology.
• CRISPR screens can identify E4 enzymes and their substrates in a genome-wide manner.
• Understanding E4 chemistry informs the design of targeted protein degradation tools such as PROTACs.
What Happens During ubiquitin-ubiquitin ligase activity?
Donor ubiquitin thioester formation
In simple terms: A ubiquitin molecule is first activated and attached to a carrier protein via a thioester bond.
Before E4 activity can occur, ubiquitin must be loaded onto a donor protein through a thioester bond between the C-terminal glycine of ubiquitin and a cysteine residue of the carrier. This step is typically performed by E1 and E2 enzymes and stores energy in the thioester bond, which is later used for chain elongation without additional ATP hydrolysis.
Acceptor ubiquitin chain recognition
In simple terms: The E4 enzyme finds an existing ubiquitin chain that will accept the new ubiquitin.
The E4 enzyme or its associated complex must recognize and bind an existing ubiquitin chain on a substrate. Ubiquitin-binding domains within E4 complexes mediate this interaction and position the acceptor chain for efficient transfer. Linkage specificity is determined by how the acceptor chain is presented to the catalytic site.
Isoenergetic transfer and chain elongation
In simple terms: The donor ubiquitin is transferred onto the acceptor chain, making the chain longer.
The catalytic step involves isoenergetic transfer of ubiquitin from the donor thioester to the acceptor ubiquitin, forming a new ubiquitin-ubiquitin linkage. This reaction does not require additional ATP because the energy is provided by the preformed thioester bond. The result is an elongated polyubiquitin chain with a defined linkage type, such as M1-linked or K48-linked chains.
Linkage-specific chain architecture
In simple terms: Different E4 enzymes build different types of ubiquitin chains with distinct cellular meanings.
E4 enzymes can generate linear (M1-linked) chains through LUBAC or K48-linked chains through CHFR, and the linkage type dictates downstream signaling or degradation outcomes. Structural studies of parkin and other RING-between-RING ligases reveal how catalytic domains enforce linkage specificity and how mutations disrupt this process.
Key Genes Involved in GO:0034450 ubiquitin-ubiquitin ligase activity
The following genes and protein complexes are experimentally linked to ubiquitin-ubiquitin ligase activity (GO:0034450) or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RNF31 (HOIP) | Catalytic subunit of LUBAC that generates M1-linked ubiquitin chains | Central to NF-kB signaling and immune disorders |
| RBCK1 (HOIL-1L) | Accessory subunit of LUBAC that stabilizes the complex | Mutations cause immunodeficiency and autoinflammation |
| SHARPIN | LUBAC component that regulates linear ubiquitination | Implicated in inflammation and cancer |
| CHFR | RING-finger E3/E4 that regulates mitotic stress checkpoint | Frequently silenced in cancers; biomarker candidate |
| PRKN (Parkin) | RING-between-RING ligase with E4-like chemistry | Mutations cause early-onset Parkinsonism |
| FBXO2 | Substrate adaptor for ubiquitin ligases | Linked to malignant tumor progression |
| UBB | Ubiquitin precursor that supplies ubiquitin moieties | Essential for all ubiquitination reactions |
| UBC | Ubiquitin precursor and stress-responsive ubiquitin source | Provides donor ubiquitin for chain elongation |
| UBE2D1 | E2 conjugating enzyme that forms thioester with ubiquitin | Donor for E4-mediated chain extension |
| UBE2L3 | E2 enzyme involved in immune signaling | Modulates LUBAC-dependent pathways |
| NEMO (IKBKG) | Ubiquitin-binding scaffold in NF-kB signaling | Recognizes linear ubiquitin chains |
| NIMIN | Plant protein targeted for degradation by U-box E3 ligases | Model for E4-like activity in plant immunity |
| VyPUB21 | Plant U-box E3 ubiquitin ligase | Enhances powdery mildew resistance |
| VCP/p97 | AAA-ATPase that processes ubiquitinated substrates | Cooperates with E4 enzymes in quality control |
| PSMD1 | Proteasome subunit that recognizes ubiquitin chains | Downstream effector of E4 activity |
| ATG5 | Autophagy-related protein linked to ubiquitin-like conjugation | Connects E4 activity to autophagy |
| SQSTM1 (p62) | Ubiquitin-binding autophagy receptor | Reads ubiquitin chains generated by E4 enzymes |
How Is ubiquitin-ubiquitin ligase activity Regulated?
Ubiquitin-ubiquitin ligase activity is regulated at multiple levels. The assembly and stability of E4 complexes such as LUBAC are controlled by subunit availability and post-translational modifications. Substrate recruitment and chain editing are influenced by ubiquitin-binding domains that recognize specific linkages. In disease contexts, mutations in catalytic domains of parkin alter E4-like chemistry and are subject to quality-control pathways. Pharmacological modulation of E4 enzymes is an active area of drug discovery, with small molecules targeting allosteric sites or catalytic pockets.
ubiquitin-ubiquitin ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHFR | Mitotic checkpoint defects and cancer | Knockout and point-mutation cell lines |
| PRKN (Parkin) | Early-onset Parkinsonism | Knock-in of catalytic-domain mutants in neurons |
| RNF31 (HOIP) | Immunodeficiency and autoinflammation | Knockout and overexpression in immune cells |
| FBXO2 | Malignant tumor progression | Knockout and overexpression in cancer lines |
| RBCK1 (HOIL-1L) | Immunodeficiency | Patient-derived knock-in models |
Cancer
Dysregulated ubiquitin-ubiquitin ligation contributes to cancer through altered degradation of oncoproteins and tumor suppressors. CHFR, which uses E4-like activity to regulate the mitotic checkpoint, is frequently silenced in cancers, leading to chromosomal instability. FBXO2 and other substrate adaptors are linked to malignant tumor progression, and LUBAC-mediated linear ubiquitination promotes NF-kB survival signaling in cancer cells.
Neurodegeneration
Parkin is a RING-between-RING ligase that uses E4-like chemistry to build ubiquitin chains on damaged mitochondria. Structural studies show that catalytic-domain mutations in parkin impair this activity and cause early-onset Parkinsonism. General defects in ubiquitination and proteasomal degradation are also associated with neurodegenerative disorders.
Immune and inflammatory disorders
LUBAC-mediated linear ubiquitination is essential for NF-kB activation, and mutations in LUBAC subunits cause immunodeficiency and autoinflammatory conditions. E4 activity therefore represents a critical node in immune homeostasis and a potential target for anti-inflammatory therapies.
From ubiquitin-ubiquitin ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of E4 activity impair NF-kB signaling? | RNF31 knockout cell line |
| How do parkin catalytic mutations affect chain assembly? | Point-mutation knock-in of PRKN |
| Can CHFR E4 activity be restored in cancer cells? | CHFR knock-in and overexpression |
| What substrates are degraded by FBXO2? | FBXO2 knockout with proteomics |
| Does LUBAC overexpression drive inflammation? | Tagged knock-in of RNF31 |
| Can E4 enzymes be targeted by small molecules? | Overexpression and reporter assays |
How to Study the ubiquitin-ubiquitin ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Ubiquitin chain linkage types | Validation of E4 products |
| CRISPR knockout screen | Genes required for E4 activity | Functional genomics |
| Knock-in point mutation | Catalytic residue function | Structure-function studies |
| Affinity proteomics | E4 complex composition | Interactome mapping |
| Ubiquitin reporter assay | Real-time chain formation | Live-cell imaging |
| RNA-seq | Transcriptional changes upon E4 loss | Pathway analysis |
| Proteasome activity assay | Degradation capacity | Quality control studies |
| High-throughput screening | Small-molecule inhibitors | Drug discovery |
Ubiquitin chain profiling by mass spectrometry
Mass spectrometry-based ubiquitin chain profiling can identify linkage types generated by E4 enzymes, including M1-linked and K48-linked chains. This method is essential for validating E4 activity in cells and tissues.
CRISPR knockout and knock-in screens
Genome-wide CRISPR screens can identify genes required for E4-mediated processes, while knock-in of point mutations allows structure-function analysis of catalytic residues. These approaches are powerful for dissecting E4 enzyme specificity.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry can map E4 complex components and substrates, revealing how LUBAC and CHFR assemble and function. Proteomics also quantifies global changes in ubiquitination upon E4 perturbation.
Imaging and reporter assays
Fluorescent ubiquitin reporters and live-cell imaging can track chain formation and localization of E4 enzymes in real time. Reporter assays are useful for high-throughput screening of E4 inhibitors.
How CRISPR Can Be Used to Study GO:0034450 ubiquitin-ubiquitin ligase activity
Knockout
CRISPR knockout of E4 enzyme genes such as RNF31 or CHFR can abolish specific ubiquitin linkages and reveal downstream signaling defects. Knockout cell lines are essential for validating E4 function in NF-kB activation and mitotic checkpoints.
Point Mutation
Point-mutation knock-in of catalytic cysteine or other key residues in parkin or CHFR allows precise dissection of E4 chemistry without confounding effects of protein loss. These models are critical for linking structural defects to disease phenotypes.
Knock-in
Tagged knock-in of E4 enzymes enables endogenous localization and interactome studies. For example, tagging RNF31 can reveal dynamic LUBAC assembly during immune signaling.
Overexpression
Overexpression of E4 enzymes or their substrates can amplify ubiquitin chain signals for biochemical detection and drug screening. Overexpression models are also used to test gain-of-function mutations in cancer.
How EDITGENE Supports ubiquitin-ubiquitin ligase activity Research
Researchers studying ubiquitin-ubiquitin ligase activity-related genes often need to determine whether a candidate gene is causally involved in chain assembly, signaling, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for ubiquitin-ubiquitin ligase activity research.
Frequently Asked Questions About ubiquitin-ubiquitin ligase activity
What is ubiquitin-ubiquitin ligase activity?
It is the enzymatic activity defined by GO:0034450 that transfers ubiquitin from a thioester-linked donor to an existing ubiquitin chain, elongating the chain without additional ATP hydrolysis.
What genes are involved in ubiquitin-ubiquitin ligase activity?
Key genes include RNF31 (HOIP), RBCK1, SHARPIN, CHFR, and PRKN (parkin), which encode E4 or E4-like enzymes.
What is the synonym for GO:0034450?
The official synonym is E4.
How is E4 activity different from E3 activity?
E4 activity uses a preformed ubiquitin thioester as the donor and an existing ubiquitin chain as the acceptor, whereas E3 enzymes typically transfer ubiquitin from an E2 to a substrate lysine.
What diseases are linked to ubiquitin-ubiquitin ligase activity?
Cancer, neurodegeneration such as Parkinsonism, and immune disorders are linked to dysregulated E4 activity.
How can I study ubiquitin-ubiquitin ligase activity in the lab?
Common methods include mass spectrometry for chain linkage profiling, CRISPR knockout screens, and ubiquitin reporter assays.
What is LUBAC and how does it relate to E4 activity?
LUBAC is a linear ubiquitin chain assembly complex that uses E4-like activity to generate M1-linked chains for NF-kB signaling.
Does parkin have E4 activity?
Parkin is a RING-between-RING ligase that uses E4-like chemistry, and catalytic-domain mutations impair its function in Parkinsonism.
Can CRISPR be used to study E4 enzymes?
Yes, CRISPR knockout, point-mutation knock-in, and overexpression models are widely used to dissect E4 enzyme function.
What are the best cell models for E4 research?
Knockout and knock-in cell lines for RNF31, CHFR, and PRKN are commonly used, along with overexpression models for biochemical assays.
Conclusion
Ubiquitin-ubiquitin ligase activity (GO:0034450) is a distinct and essential molecular function that extends ubiquitin chains using a preformed thioester donor. Its representative enzymes, including LUBAC, CHFR, and parkin, control critical processes such as NF-kB signaling, mitotic checkpoints, and mitochondrial quality control. Dysregulation of E4 activity is linked to cancer, neurodegeneration, and immune disorders, making it a compelling target for therapeutic development. CRISPR-based models, combined with mass spectrometry and proteomics, provide powerful tools to dissect E4 mechanisms and identify new drug targets. EDITGENE offers comprehensive services to generate knockout, point-mutation, knock-in, and overexpression models for ubiquitin-ubiquitin ligase activity research.
References
- 1. Hurley JH et al.. 2006. Ubiquitin-binding domains.. Biochem J 399(3):361-72 PMID: 17034365
- 2. Sasaki K et al.. 2023. LUBAC-mediated linear ubiquitination in tissue homeostasis and disease.. J Biochem 174(2):99-107 PMID: 37279649
- 3. Chaturvedi P et al.. 2002. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity.. Cancer Res 62(6):1797-801 PMID: 11912157
- 4. Zhang J et al.. 2025. Research advancements regarding the relationship between FBXO2 and malignant tumors (Review).. Mol Med Rep 32(6) PMID: 40999994
- 5. Paiva SL et al.. 2018. Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site.. J Med Chem 61(2):405-421 PMID: 28076680
- 6. Wang L et al.. 2024. The Vitis yeshanensis U-box E3 ubiquitin ligase VyPUB21 enhances resistance to powdery mildew by targeting degradation of NIM1-interacting (NIMIN) protein.. Plant Cell Rep 43(4):93 PMID: 38467927
- 7. Jiang YH et al.. 2004. Human disorders of ubiquitination and proteasomal degradation.. Curr Opin Pediatr 16(4):419-26 PMID: 15273504
- 8. Wagner JP et al.. 2025. Structural basis for the pathogenicity of parkin catalytic domain mutants.. J Biol Chem 301(1):108051 PMID: 39631693
